Industry

14.05.2021

 

Overall proportion of industry and non-industry income is: 86.4% industry income vs 13.6% non-industry income. Please find below a list of Industry Partners and related contributions for the financial year 2019:

Industry1 related income (2019)

Name of company/funder Amount of income2 Percentage of overall budget
Almirall € 10,000 0,8%
Biogen € 150,055 12,4%
Bristol-Myers-Squibb (BMS – formerly Celgene) € 167,796 0,9%
Canopy Growth € 11,310 13,6%
Icometrix € 5,000 0,4%
MedDay € 15,000 1,2%
Merck € 159,710 13,2%
Mylan € 30,000 2,5%
Novartis € 241,222 19,9%
Quanterix € 5,000 0,4%
Roche € 117,000 9,7%
Sanofi-Genzyme € 136,800 11,3%
Subtotal € 1,211,105 86,4%
[1] Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.
[2] This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

 

Code of Conduct

On a regular basis, EMSP also collaborates with the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Our approach is transparent and rules-based, as set out in our Code of Conduct.